<p>美国资本财富顾问公司在最近向证券交易委员会的披露中表示，在第三季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持仓减少了 30.9%。该机构投资者在本季度出售了 21,256 股后，持有 47,638 股该公司的股票。美国资本财富顾问公司在艾伯维的持股在最近一个季度末的价值为 11,030,000 美元。</p>
<ul>
<li>3 只分析师看好的 2026 年股息增长股票</li>
</ul>
<p>其他几家大型投资者最近也对 ABBV 的持仓进行了调整。挪威银行在第二季度购买了价值约 42.882 亿美元的艾伯维新股。劳雷尔财富顾问公司在第二季度将其在艾伯维的持仓增加了 18,384.4%。劳雷尔财富顾问公司现在拥有 5,705,964 股该公司的股票，价值为 1,059,141,000 美元，此前在上个季度又购买了 5,675,095 股。Assenagon 资产管理公司在第二季度将其在艾伯维的股份增加了 550.9%。Assenagon 资产管理公司现在拥有 4,332,054 股该公司的股票，价值为 804,116,000 美元，此前在此期间又收购了 3,666,521 股。先锋集团在第二季度将其在艾伯维的股份增加了 1.9%。先锋集团现在拥有 177,298,707 股该公司的股票，价值为 32,910,186,000 美元，此前在上个季度又收购了 3,380,842 股。最后，金斯顿资本合伙公司在第二季度购买了价值 581,817,000 美元的艾伯维新股。目前 70.23% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>艾伯维股票上涨 2.1%</h2>
<p>艾伯维（NYSE:ABBV）股票在周五开盘价为 227.44 美元。艾伯维公司的 52 周低点为 164.39 美元，52 周高点为 244.81 美元。该公司的 50 日移动平均价格为 226.63 美元，200 日移动平均价格为 210.98 美元。公司的速动比率为 0.60，流动比率为 0.72，债务与股本比率为 44.14。该股票的市值为 4019.8 亿美元，市盈率为 172.30，市盈增长比率为 1.27，贝塔值为 0.36。</p>
<ul>
<li>股息强劲：3 只适合长期投资的蓝筹股</li>
</ul>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近于 10 月 31 日公布了季度财报。公司报告本季度每股收益为 1.86 美元，超出分析师一致预期的 1.77 美元，超出幅度为 0.09 美元。该业务本季度的收入为 157.8 亿美元，而分析师预期为 155.8 亿美元。艾伯维的净利润率为 4.00%，股本回报率为 3,216.47%。公司的收入同比增长了 9.1%。去年同期，该业务的每股收益为 3.00 美元。艾伯维已将其 2025 年第四季度的指导目标设定为每股收益 3.320-3.360 美元。整体来看，股票研究分析师预测艾伯维公司在当前财政年度的每股收益将达到 12.31 美元。</p>
<h2>艾伯维增加股息</h2>
<p>该公司还最近宣布了一项季度股息，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）的股东将获得 1.73 美元的股息。这代表着每年 6.92 美元的股息和 3.0% 的股息收益率。除息日期为 1 月 16 日（星期五）。这比艾伯维之前的季度股息 1.64 美元有所增加。艾伯维的股息支付比率（DPR）目前为 496.97%。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
<p>几位股票分析师对该股票发布了报告。摩根士丹利在 12 月 12 日（星期五）的报告中将艾伯维的目标股价从 261.00 美元上调至 269.00 美元，并给予该股票 “增持” 评级。雷蒙德·詹姆斯金融在 11 月 3 日（星期一）的研究报告中设定了艾伯维的目标股价为 256.00 美元。摩根大通在 11 月 3 日（星期一）的研究报告中将艾伯维的目标股价从 250.00 美元上调至 260.00 美元，并给予该股票 “增持” 评级。汇丰银行在 12 月 10 日（星期三）的研究报告中将艾伯维的评级从 “持有” 上调至 “买入”，并将其目标股价从 225.00 美元上调至 265.00 美元。最后，贝伦贝格银行在 9 月 17 日（星期三）的研究报告中将艾伯维的评级从 “持有” 上调至 “买入”，并将其目标股价从 170.00 美元上调至 270.00 美元。三位分析师对该股票给予了强烈买入评级，十三位给予了买入评级，八位给予了持有评级。根据 MarketBeat.com 的数据，艾伯维目前的共识评级为 “适度买入”，共识目标股价为 245.84 美元。</p>
<p><strong>阅读我们最新的艾伯维股票分析</strong></p>
<h2>艾伯维简介</h2>
<p>（免费报告）</p>
<p>艾伯维是一家全球性的、以研究为驱动的生物制药公司，于 2013 年从雅培实验室分拆而成，总部位于伊利诺伊州北芝加哥。该公司专注于发现、开发和商业化针对复杂且常常是慢性医疗条件的治疗方案。其业务涵盖研究与开发、制造、监管事务和商业化，重点是将专业药物推向多个治疗领域的市场。</p>
<p>艾伯维的产品组合和研发管道涵盖多个主要治疗类别，包括免疫学、肿瘤学、神经科学、病毒学和女性健康。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票比艾伯维更好</li>
<li>什么是热门股票？热门股票解释</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
<li>什么是便士股票？全面指南</li>
<li>MarketBeat 周回顾 – 12/15 - 12/19</li>
<li>如何在购买前评估股票</li>
<li>耐克在收益上超出预期，但在中国面临挑战并遭遇关税</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>美国资本财富顾问公司（U.S. Capital Wealth Advisors LLC）在第三季度将其在艾伯维（AbbVie Inc.）的持股减少了 30.9%，目前持有 47,638 股，价值 11,030,000 美元。艾伯维的股票开盘价为 227.44 美元，52 周价格区间为 164.39 美元至 244.81 美元。分析师预测公司将实现增长，摩根士丹利（Morgan Stanley）、摩根大通（JPMorgan）、汇丰银行（HSBC）和贝伦贝格银行（Berenberg Bank）均上调了目标价格。艾伯维将每股股息提高至 1.73 美元，收益率为 3.0%。该公司报告第三季度每股收益为 1.86 美元，超出预期</p>

<p>U.S. Capital Wealth Advisors LLC decreased its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 30.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 47,638 shares of the company's stock after selling 21,256 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in AbbVie were worth $11,030,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>美国资本财富顾问公司在最近向证券交易委员会的披露中表示，在第三季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持仓减少了 30.9%。该机构投资者在本季度出售了 21,256 股后，持有 47,638 股该公司的股票。美国资本财富顾问公司在艾伯维的持股在最近一个季度末的价值为 11,030,000 美元。</p>
</div><ul>
<li>3 Dividend Growth Stocks Analysts Are Upgrading for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只分析师看好的 2026 年股息增长股票</li>
</ul>
</div><p>Several other large investors have also recently made changes to their positions in ABBV. Norges Bank bought a new position in AbbVie during the 2nd quarter valued at about $4,288,200,000. Laurel Wealth Advisors LLC increased its position in AbbVie by 18,384.4% in the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company's stock worth $1,059,141,000 after purchasing an additional 5,675,095 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of AbbVie by 550.9% in the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company's stock valued at $804,116,000 after acquiring an additional 3,666,521 shares during the period. Vanguard Group Inc. grew its stake in AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company's stock worth $32,910,186,000 after acquiring an additional 3,380,842 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new position in shares of AbbVie during the 2nd quarter worth $581,817,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也对 ABBV 的持仓进行了调整。挪威银行在第二季度购买了价值约 42.882 亿美元的艾伯维新股。劳雷尔财富顾问公司在第二季度将其在艾伯维的持仓增加了 18,384.4%。劳雷尔财富顾问公司现在拥有 5,705,964 股该公司的股票，价值为 1,059,141,000 美元，此前在上个季度又购买了 5,675,095 股。Assenagon 资产管理公司在第二季度将其在艾伯维的股份增加了 550.9%。Assenagon 资产管理公司现在拥有 4,332,054 股该公司的股票，价值为 804,116,000 美元，此前在此期间又收购了 3,666,521 股。先锋集团在第二季度将其在艾伯维的股份增加了 1.9%。先锋集团现在拥有 177,298,707 股该公司的股票，价值为 32,910,186,000 美元，此前在上个季度又收购了 3,380,842 股。最后，金斯顿资本合伙公司在第二季度购买了价值 581,817,000 美元的艾伯维新股。目前 70.23% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>AbbVie Stock Up 2.1%</h2>
<div class="lb-trans"><h2>艾伯维股票上涨 2.1%</h2>
</div><p>Shares of NYSE:ABBV opened at $227.44 on Friday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The firm's 50 day moving average price is $226.63 and its 200 day moving average price is $210.98. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The stock has a market cap of $401.98 billion, a price-to-earnings ratio of 172.30, a price-to-earnings-growth ratio of 1.27 and a beta of 0.36.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV）股票在周五开盘价为 227.44 美元。艾伯维公司的 52 周低点为 164.39 美元，52 周高点为 244.81 美元。该公司的 50 日移动平均价格为 226.63 美元，200 日移动平均价格为 210.98 美元。公司的速动比率为 0.60，流动比率为 0.72，债务与股本比率为 44.14。该股票的市值为 4019.8 亿美元，市盈率为 172.30，市盈增长比率为 1.27，贝塔值为 0.36。</p>
</div><ul>
<li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li>
</ul>
<div class="lb-trans"><ul>
<li>股息强劲：3 只适合长期投资的蓝筹股</li>
</ul>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company's revenue was up 9.1% on a year-over-year basis. During the same period last year, the business earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近于 10 月 31 日公布了季度财报。公司报告本季度每股收益为 1.86 美元，超出分析师一致预期的 1.77 美元，超出幅度为 0.09 美元。该业务本季度的收入为 157.8 亿美元，而分析师预期为 155.8 亿美元。艾伯维的净利润率为 4.00%，股本回报率为 3,216.47%。公司的收入同比增长了 9.1%。去年同期，该业务的每股收益为 3.00 美元。艾伯维已将其 2025 年第四季度的指导目标设定为每股收益 3.320-3.360 美元。整体来看，股票研究分析师预测艾伯维公司在当前财政年度的每股收益将达到 12.31 美元。</p>
</div><h2>AbbVie Increases Dividend</h2>
<div class="lb-trans"><h2>艾伯维增加股息</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie's previous quarterly dividend of $1.64. AbbVie's dividend payout ratio (DPR) is currently 496.97%.</p>
<div class="lb-trans"><p>该公司还最近宣布了一项季度股息，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）的股东将获得 1.73 美元的股息。这代表着每年 6.92 美元的股息和 3.0% 的股息收益率。除息日期为 1 月 16 日（星期五）。这比艾伯维之前的季度股息 1.64 美元有所增加。艾伯维的股息支付比率（DPR）目前为 496.97%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
</div><p>Several equities analysts have issued reports on the stock. Morgan Stanley lifted their price target on shares of AbbVie from $261.00 to $269.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, December 12th. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday, November 3rd. JPMorgan Chase &amp; Co. boosted their price objective on AbbVie from $250.00 to $260.00 and gave the stock an &#34;overweight&#34; rating in a research note on Monday, November 3rd. HSBC raised shares of AbbVie from a &#34;hold&#34; rating to a &#34;buy&#34; rating and boosted their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Finally, Berenberg Bank upgraded AbbVie from a &#34;hold&#34; rating to a &#34;buy&#34; rating and upped their price target for the stock from $170.00 to $270.00 in a research note on Wednesday, September 17th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat.com, AbbVie currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $245.84.</p>
<div class="lb-trans"><p>几位股票分析师对该股票发布了报告。摩根士丹利在 12 月 12 日（星期五）的报告中将艾伯维的目标股价从 261.00 美元上调至 269.00 美元，并给予该股票 “增持” 评级。雷蒙德·詹姆斯金融在 11 月 3 日（星期一）的研究报告中设定了艾伯维的目标股价为 256.00 美元。摩根大通在 11 月 3 日（星期一）的研究报告中将艾伯维的目标股价从 250.00 美元上调至 260.00 美元，并给予该股票 “增持” 评级。汇丰银行在 12 月 10 日（星期三）的研究报告中将艾伯维的评级从 “持有” 上调至 “买入”，并将其目标股价从 225.00 美元上调至 265.00 美元。最后，贝伦贝格银行在 9 月 17 日（星期三）的研究报告中将艾伯维的评级从 “持有” 上调至 “买入”，并将其目标股价从 170.00 美元上调至 270.00 美元。三位分析师对该股票给予了强烈买入评级，十三位给予了买入评级，八位给予了持有评级。根据 MarketBeat.com 的数据，艾伯维目前的共识评级为 “适度买入”，共识目标股价为 245.84 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on AbbVie</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的艾伯维股票分析</strong></p>
</div><h2>AbbVie Profile</h2>
<div class="lb-trans"><h2>艾伯维简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.</p>
<div class="lb-trans"><p>艾伯维是一家全球性的、以研究为驱动的生物制药公司，于 2013 年从雅培实验室分拆而成，总部位于伊利诺伊州北芝加哥。该公司专注于发现、开发和商业化针对复杂且常常是慢性医疗条件的治疗方案。其业务涵盖研究与开发、制造、监管事务和商业化，重点是将专业药物推向多个治疗领域的市场。</p>
</div><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p>
<div class="lb-trans"><p>艾伯维的产品组合和研发管道涵盖多个主要治疗类别，包括免疫学、肿瘤学、神经科学、病毒学和女性健康。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>What Are Trending Stocks? Trending Stocks Explained</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
<li>What is a penny stock? A comprehensive guide</li>
<li>MarketBeat Week in Review – 12/15 - 12/19</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比艾伯维更好</li>
<li>什么是热门股票？热门股票解释</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
<li>什么是便士股票？全面指南</li>
<li>MarketBeat 周回顾 – 12/15 - 12/19</li>
<li>如何在购买前评估股票</li>
<li>耐克在收益上超出预期，但在中国面临挑战并遭遇关税</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

美国资本财富顾问有限责任公司减少了其在艾伯维公司（AbbVie Inc.）的股票持有量 $ABBV